ClinPGx Blog (Page 39)

Sign in Subscribe

More issues

New EGFR VIP Summary Published in PG&G

The epidermal growth factor receptor (EGFR) is involved in the growth of many epithelial malignancies, such as non-small-cell lung cancer (NSCLC), pancreatic and colorectal cancer. It has therefore been a key target for the development of cancer therapeutics. These include tyrosine kinase inhibitors (gefinitib and erolinitib) and monoclonal antibodies (cetuximab

CPIC publishes guidelines for DPYD and fluoropyrimidines

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines for the use of genetic test results for DPYD in fluoropyrimidine dosing. The guideline in Clinical Pharmacology and Therapeutics recommends strategies for drug dosing or alternative drug choice in cancer patients who have known variants in the dihydropyrimidine dehydrogenase (DPYD) gene

Tamoxifen Pharmacokinetic Pathway Published

Tamoxifen, a selective estrogen receptor modulator, is used in the treatment and prevention of estrogen receptor positive breast cancer. The paper detailing the pharmacokinetic pathway of tamoxifen has been published by PG&G and can be found online. The pathway can also be found on our website. View all

CYP2C8 VIP published in PG&G

CYP2C8 is a member of the cytochrome P450 family of drug metabolizing enzymes. It plays a major role in the metabolism of many commonly used drugs. Several CYP2C8 SNPs have been associated with variability in metabolism, disposition and response for drugs such as repaglinide, rosiglitazone, pioglitazone, paclitaxel, bisphosphonates, amiodarone and

New PharmGKB VIP Summary: NAT2

N-acetyltransferase enzymes (NAT1 and NAT2) are involved in the metabolism and detoxification of xenobiotics. NAT2 is predominantly expressed in the liver and has a role in the metabolism of numerous therapeutic drugs including caffeine and BiDil. Genetic variants in the NAT2 gene result in a slow, intermediate or rapid acetylator

Tacrolimus and cyclosporine pathways published

Tacrolimus and cyclosporine are two immunosuppressants given to solid organ transplant patients to prevent allograft rejection. A PharmGKB summary discussing the pharmacokinetics, pharmacodynamics and pharmacogenetics of these two drugs has been published in Pharmacogenetics and Genomics, and is now available to read online ahead of print. The summary also includes

PharmGKB PGx summaries now available in the Genetic Testing Registry

The Genetic Testing Registry (GTR) now contains summaries written by PharmGKB Curators regarding the association between genes and drug responses that have CPIC therapeutic recommendations. These can be found on the GTR website under Conditions/Phenotypes and links to relevant clinical tests are provided on each page: * Warfarin response * Codeine

Visualizing Levels of Evidence

PharmGKB Clinical Annotations provide a summary of an association between a genetic variant and a drug response. Each is assigned a level of evidence by our curators, based on established criteria. We have created an illustration to help users understand the 4 levels of evidence:

CPIC guidelines now posted on guidelines.gov

Six CPIC PGx-based dosing guidelines are now available on the National Guideline Clearinghouse website, a public resource for evidence-based clinical guidelines, an initiative of the Agency for Healthcare Research and Quality, US Department of Health Services. View the CPIC guidelines on the NGC website: * CYP2D6, CYP2C19 & tricyclic antidepressants * CYP2D6

"Jack of all trades" drug pathway published

Methylene blue has many clinical uses including the treatment of methemoglobinemia and malaria, as a diagnostic dye and even has potential as a therapy for Alzheimer's disease. A PharmGKB summary combining the methylene blue pharmacodynamics pathway with the oxidative stress regulatory and pentose phosphate pathways in red blood